CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease Syndrome: a Prospective Clinical Cohort Study

Approximately 10% to 20% of patients optimally treated for early Lyme disease develop persistent symptoms of unknown pathophysiology termed posttreatment Lyme disease syndrome (PTLDS). The objective of this study was to investigate associations between PTLDS and immune mediator levels during acute i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Vaccine Immunol
Autors principals: Aucott, John N., Soloski, Mark J., Rebman, Alison W., Crowder, Lauren A., Lahey, Lauren J., Wagner, Catriona A., Robinson, William H., Bechtold, Kathleen T.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2016
Matèries:
Clinical Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5014924/
https://ncbi.nlm.nih.gov/pubmed/27358211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.00071-16
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars